Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Cara Therapeutics reports solid Q4 earnings amidst growth opportunities

Cara Therapeutics showcased strong revenue growth and positive feedback on KORSUVA injection sales in Q4 2022.
While facing challenges such as demand instability and regulatory uncertainties, the company remains confident in its growth prospects.
Strategic investments, milestone anticipation, and financial stability position Cara well for future value creation and market expansion.

Cara Therapeutics reports strong Q1 revenue, optimistic about pipeline growth

Cara Therapeutics delivered solid revenue in Q1 2023 driven by the successful launch of KORSUVA and Kapruvia. While facing increased operating expenses, the company remains optimistic about its pipeline's potential. Strategic focus on KORSUVA's success and ongoing R&D efforts position Cara for future growth.

Cara Therapeutics reports solid Q2 earnings amidst regulatory uncertainties

Cara Therapeutics posted strong financial performance in Q2 2023, driven by robust net sales and cash reserves, with a focus on maximizing shareholder value.
The company faces challenges related to potential CMS changes and European market dynamics but sees opportunities in international expansion and regulatory engagement.
Overall, Cara Therapeutics remains optimistic about the commercial prospects of its key products and pipeline, aiming for sustained growth and market leadership.

Cara Therapeutics extends cash runway, faces funding challenges ahead

Cara Therapeutics reports strong financials with extended cash runway. Progress in late-stage programs and successful monetization of royalties. Facing challenges with funding limitations and uncertainties around data releases.

Cara Therapeutics extends cash runway to 2026 amidst revenue challenges

Cara Therapeutics strategically focused on NP and oral DSK programs to drive growth.
Strong demand for KORSUVA injection but challenges from reimbursement changes.
Confidence in NP program and potential partnerships signal future opportunities.
Financially extended runway to 2026 but facing liquidity challenges with $1.8 million cash.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q4 2019 Results - Earnings Call Transcript

Scotts Miracle-Gro

These stocks went in opposite directions in 2019. Will that trend continue this year?

Better Buy: Cara Therapeutics vs. Scotts Miracle-Gro Company

TG Therapeutics

These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.

2 Top Stocks Under $20

GW Pharmaceuticals

Despite their differences, there's a lot of good things going on for both of these health companies.

Better Buy:  GW Pharmaceuticals vs. Cara Therapeutics

Arena Pharmaceuticals

Corbus Pharmaceuticals Holdings

Cronos Group

Greenlane Holdings

Marrone Bio Innovations

New Age Beverages

Intec Parent

OrganiGram Holdings Inc.

Psychemedics

SNDL Inc.

Tilray Brands

Therapix Biosciences

Village Farms International

Zynerba Pharmaceuticals

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Top Marijuana Stocks on the NASDAQ

What does the future look like for this promising biotech stock?

Where Will Cara Therapeutics Be in 5 Years?

Cara Therapeutics Is An Undervalued Asset In 2020

STAMFORD, Conn., Jan.  08, 2020  (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 5:00 p.m. PT (8:00 p.m. ET) in San Francisco, CA.

Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Adverum Biotechnologies

Green Dot

Innovative Industrial Properties

iShares Russell 2000 ETF

MFAM Small-Cap Growth ETF

SPDR S&P 500 ETF Trust

Vanguard S&P Small-Cap 600 ETF

Small-cap stocks have been subpar performers of late, but that weakness has only made the opportunity more compelling.

Why Your 2020 Resolution Should Be to Buy More Small-Cap Stocks

Fresenius Medical Care

These two companies could be headed in vastly different directions in 2020.

Better Buy: Cara Therapeutics vs. Fresenius

Both of these biotechs could become smash hits, but which is better?

Better Buy: Cara Therapeutics vs. Corbus Pharmaceuticals

NanoString Technologies

Portola Pharmaceuticals

These three small companies have the potential to make you a lot of money.

3 Small-Cap Healthcare Stocks With Large-Cap Potential

Cara Therapeutics: Recent Stock Price Plunge Was A Bit Exaggerated

Allergan

Alector Inc

Amarin Corporation Plc

Athenex

Biohaven Pharmaceutical Hld

Global Blood Therapeutics

Intra-Cellular Therapies

Novartis

Puma Biotechnology

Protagonist Therapeutics

Proteostasis Therapeutics

Rocket Pharma

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Biotech’s Year-End To-Do List

STAMFORD, Conn., Dec.  06, 2019  (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved the grant of non-qualified stock options to purchase an aggregate of 47,500 shares of common stock, to be distributed among two new non-executive employees, pursuant to Cara’s 2019 Inducement Plan.

Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

Plug Power

Peloton

On a tough day on Wall Street, these stocks got hit especially hard.

Why Peloton Interactive, Plug Power, and Cara Therapeutics Slumped Today

Investors aren't happy with the company's mixed results from a midstage study of Oral Korsuva.

Why Cara Therapeutics Stock Is Plunging Today

Cara Therapeutics Inc. CARA, -0.38% announced positive results Tuesday from a mid-stage trial of a treatment of pruritis in patients with chronic kidney disease (CKD), an itchiness associated with the kidney disorder.

Cara Therapeutics announces positive results in trial of treatment for chronic kidney disease

– Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) ––  Oral KORSUVA™ well-tolerated after 12 weeks of treatment ––  Conference call today at 8:30 a.m. ET –

Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

Amyris

Aphria

These are the marijuana stocks with the best value, fastest growth, and most momentum for November.

Top Marijuana Stocks for November 2019

- Treatment with KORSUVA Injection resulted in statistically significant reduction in pruritus intensity and improvement in itch-related quality of life measures vs placebo for both primary and secondary endpoints -

Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine

The biotech's financial performance in Q3 really doesn't matter. But its pipeline progress for Korsuva does.

Cara Therapeutics Q3 Update: Forget the Financials and Focus on the Pipeline

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2019 Results - Earnings Call Transcript

Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.

Why This Just Might Be the Biggest Week for CARA Stock

These stocks have a lot of potential growth, but which one is more of a sure thing today?

Better Buy: Cara Therapeutics vs. Scotts Miracle-Gro

News for Cara Therapeutics Stock (CARA)